Loading organizations...
§ Private Profile · Alameda, CA, USA
Clinical-stage biotechnology company developing off-the-shelf allogeneic cell therapies for oncology, focused on solid tumors and blood cancers.
Founded in 2017 by Sonny Hsiao, Patrick Yang, and Nobel Laureate Carolyn Bertozzi, Acepodia is a clinical-stage biotechnology company developing off-the-shelf allogeneic cell therapies for oncology applications. Headquartered in San Mateo, California, with additional research operations in Taiwan, the enterprise utilizes a proprietary antibody-cell conjugation platform to link tumor-targeting mechanisms directly to natural killer and gamma delta T cells. This innovative approach creates highly accessible treatments specifically designed for patients battling various solid tumors and hematologic cancers. Operating with a workforce of approximately 100 employees, the firm has secured $259 million in total funding, including a recent $109 million Series C round, to advance its investigational new drug applications through clinical trials. The organization is backed by prominent institutional investors including Eight Roads Ventures and Digital Garage, while maintaining strategic pharmaceutical partnerships with entities such as JW Therapeutics.
Acepodia has raised $156.0M across 2 funding rounds.
Acepodia has raised $156.0M in total across 2 funding rounds.
Acepodia has raised $156.0M across 2 funding rounds. Most recently, it raised $109.0M Series C in December 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 2, 2021 | $109M Series C | Samuel Chen | — | Announced |
| Mar 16, 2021 | $47M Series B | — | 8VC, CDIB Capital Group, DEFTA Partners, Wayne Holman | Announced |
Acepodia has raised $156.0M in total across 2 funding rounds.
Acepodia's investors include Samuel Chen, 8VC, CDIB Capital Group, DEFTA Partners, Wayne Holman.